000290075 001__ 290075
000290075 005__ 20250731110223.0
000290075 0247_ $$2doi$$a10.1002/ijc.34988
000290075 0247_ $$2pmid$$apmid:38721724
000290075 0247_ $$2ISSN$$a0020-7136
000290075 0247_ $$2ISSN$$a1097-0215
000290075 0247_ $$2altmetric$$aaltmetric:163339697
000290075 037__ $$aDKFZ-2024-00974
000290075 041__ $$aEnglish
000290075 082__ $$a610
000290075 1001_ $$00000-0001-9899-1022$$aJanssen, Maike$$b0
000290075 245__ $$aTreatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
000290075 260__ $$aBognor Regis$$bWiley-Liss$$c2024
000290075 3367_ $$2DRIVER$$aarticle
000290075 3367_ $$2DataCite$$aOutput Types/Journal article
000290075 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726657227_11602
000290075 3367_ $$2BibTeX$$aARTICLE
000290075 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290075 3367_ $$00$$2EndNote$$aJournal Article
000290075 500__ $$a2024 Aug 15;155(4):618-626
000290075 520__ $$aImmunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS-CoV-2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS-CoV-2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID-19 infection. Here, we report on a series of 21 immunocompromised patients with COVID-19-most of them hematologic malignancies-treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS-CoV-2-antibody-containing plasma could clear SARS-CoV-2 infection in 16 out of 21 immunocompromised patients even if COVID-19-specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS-CoV-2 infection. Ten patients were major responders defined as an increase delta(d)Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS-CoV-2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10-24.25) to a median value of 29.57 (IQR = 27.55-34.63; p = <.0001) in the major response subgroup. Furthermore, when treated a second time with C/VP, even 4 out of 5 of the initial nonresponders showed an increase in Ct-values from a median value of 23.13 (IQR = 17.75-28.05) to a median value of 32.79 (IQR = 31.75-33.75; p = .013). Our results suggest that C/VP could be a feasible treatment of COVID-19 infection in patients with hematologic malignancies who did not respond to antiviral treatment.
000290075 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000290075 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290075 650_7 $$2Other$$aCOVID‐19
000290075 650_7 $$2Other$$aSARS‐CoV‐2‐antibody containing plasma
000290075 650_7 $$2Other$$aprolonged SARS‐CoV‐2 infection
000290075 7001_ $$aLeo, Albrecht$$b1
000290075 7001_ $$aWolf, Cornelia$$b2
000290075 7001_ $$aStenzinger, Miriam$$b3
000290075 7001_ $$aBartenschlager, Marie$$b4
000290075 7001_ $$aBrandt, Juliane$$b5
000290075 7001_ $$aSauer, Sandra$$b6
000290075 7001_ $$aSchmitt, Michael$$b7
000290075 7001_ $$aDreger, Peter$$b8
000290075 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard F$$b9$$udkfz
000290075 7001_ $$aDenkinger, Claudia M$$b10
000290075 7001_ $$0P:(DE-HGF)0$$aMüller-Tidow, Carsten$$b11
000290075 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34988$$gp. ijc.34988$$n4$$p618-626$$tInternational journal of cancer$$v155$$x0020-7136$$y2024
000290075 8564_ $$uhttps://inrepo02.dkfz.de/record/290075/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Janssen%20-%20Treatment%20of%20chronic%20COVID%E2%80%9019%20with%20convalescent%20postvaccination%20plasma%20in.pdf
000290075 8564_ $$uhttps://inrepo02.dkfz.de/record/290075/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Janssen%20-%20Treatment%20of%20chronic%20COVID%E2%80%9019%20with%20convalescent%20postvaccination%20plasma%20in.pdf?subformat=pdfa$$xpdfa
000290075 909CO $$ooai:inrepo02.dkfz.de:290075$$pVDB
000290075 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000290075 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000290075 9141_ $$y2024
000290075 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000290075 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000290075 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000290075 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000290075 9201_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x0
000290075 980__ $$ajournal
000290075 980__ $$aVDB
000290075 980__ $$aI:(DE-He78)W010-20160331
000290075 980__ $$aUNRESTRICTED